![]() |
![]() |
Legal status
Patent not validated
(51) | INT.CL. | A61K 38/36 | (2006.01) |
A61P 7/04 | (2018.01) | ||
A61P 7/04 | (2006.01) | ||
A61K 38/36 | (2013.01) |
(11) | Number of the document | 3648787 |
(13) | Kind of document | T |
(96) | European patent application number | 18746457.3 |
Date of filing the European patent application | 2018-07-09 | |
(97) | Date of publication of the European application | 2020-05-13 |
(45) | Date of publication and mention of the grant of the patent | 2024-10-30 |
(46) | Date of publication of the claims translation |
(86) | Number | PCT/US2018/041319 |
Date | 2018-07-09 |
(87) | Number | WO 2019/010496 |
Date | 2019-01-10 |
(30) | Number | Date | Country code |
201762530024 P | 2017-07-07 | US | |
201762546999 P | 2017-08-17 | US |
(72) |
CHAPMAN, Miranda , US
EWENSTEIN, Bruce , US
PLODER, Bettina , AT
|
(73) |
Takeda Pharmaceutical Company Limited ,
1-1, Doshomachi 4-chome,
Chuo-ku,, Osaka-shi, Osaka,
JP
|
(54) | TREATMENT OF PATIENTS WITH SEVERE VON WILLEBRAND DISEASE UNDERGOING ELECTIVE SURGERY BY ADMINISTRATION OF RECOMBINANT VWF |
TREATMENT OF PATIENTS WITH SEVERE VON WILLEBRAND DISEASE UNDERGOING ELECTIVE SURGERY BY ADMINISTRATION OF RECOMBINANT VWF |